---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-013170"
form_type: "8-K"
ticker: "HOOK"
cik: "0001760542"
company_name: "HOOKIPA Pharma Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:59:00.664298+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# HOOKIPA Q2 2022 revenue $2.7M, net loss $16.4M; FDA accepts IND for HB-300, HB-200 Phase 2 underway

## Summary
- Revenue $2.7M, down from $5.4M YoY due to lower cost reimbursements from Gilead collaboration.
- Net loss $16.4M versus $17.2M in Q2 2021; R&D expenses decreased to $16.1M from $19.6M.
- Cash, equivalents and restricted cash $118.9M at June 30, 2022, up from $66.9M at Dec 31, 2021.
- FDA accepted IND for HB-300 (metastatic castration-resistant prostate cancer) and Drug Master File for platform.
- HB-200 Phase 1 met all endpoints; Phase 2 started; initial data with pembrolizumab expected H2 2022.

## SEC filing metadata
- accession: 0001558370-22-013170
- form_type: 8-K
- ticker: HOOK
- cik: 0001760542
- company_name: HOOKIPA Pharma Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1760542/000155837022013170/0001558370-22-013170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1760542/000155837022013170/hook-20220811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-013170
- JSON: https://secwatch.observer/filing/0001558370-22-013170.json
- Plain text: https://secwatch.observer/filing/0001558370-22-013170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.